Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not completely understood which patients might benefit from neoadjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: AlSaleh, Khalid, Al Zahwahry, Heba, Bounedjar, Adda, Oukkal, Mohammed, Saadeddine, Ahmed, Mahfouf, Hassen, Bouzid, Kamel, Bensalem, Assia, Filali, Taha, Abdel-Razeq, Hikmat, Larbaoui, Blaha, Kandil, Alaa, Abulkhair, Omalkhair, Al Foheidi, Meteb, Errihani, Hassan, Ghosn, Marwan, Abdel-Aziz, Nashwa, Arafah, Maria, Boussen, Hamouda, Dabouz, Farida, Rasool, Haleem, Bahadoor, Mohun, Ayari, Jihen, Kullab, Sharif, Nabholtz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457874/
https://www.ncbi.nlm.nih.gov/pubmed/34086481
http://dx.doi.org/10.1200/GO.20.00575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457874/
https://www.ncbi.nlm.nih.gov/pubmed/34086481
http://dx.doi.org/10.1200/GO.20.00575

Ejemplares similares